Search results
People also ask
Why is erythromycin a bacteriostatic antibiotic?
What bacteria does erythromycin kill?
Is erythromycin effective against Gram-positive bacteria?
Jul 2, 2023 · Erythromycin is a bacteriostatic antibiotic, which means it prevents the further growth of bacteria rather than directly destroying them. This action occurs by inhibiting protein synthesis. Erythromycin binds to the 23S ribosomal RNA molecule in the 50S subunit of the bacterial ribosome; this causes a blockage in peptide chain synthesis ...
- Bacteriostatic Antibiotics - StatPearls - NCBI Bookshelf
[7] [8] Erythromycin has poor activity against gram-negative...
- Following the Mechanisms of Bacteriostatic versus ...
Antibiotics cure infections by influencing bacterial growth...
- Bacteriostatic Antibiotics - StatPearls - NCBI Bookshelf
Aug 14, 2023 · [7] [8] Erythromycin has poor activity against gram-negative and anaerobic organisms. However, it is extremely effective against atypical pathogens and has some activity against Neisseria spp. Clarithromycin has a similar spectrum of activity to erythromycin, with additional activity against some staph and strep species.
- John Loree, Sarah L. Lappin
- 2023/08/14
- Upstate University Hospital
Erythromycin displays bacteriostatic activity or inhibits growth of bacteria, especially at higher concentrations. By binding to the 50s subunit of the bacterial rRNA complex, protein synthesis and subsequent structure and function processes critical for life or replication are inhibited. [34]
- C₃₇H₆₇NO₁₃
- AU: A
- liver (under 5% excreted unchanged)
- Eryc, Erythrocin, others
- Introduction
- Methods
- Results
- Discussion
- Acknowledgements
The distinction between bactericidal and bacteriostatic antibiotics is a successful concept to discriminate antibiotics that kill bacteria—‘bactericidal’—from antibiotics that inhibit bacterial growth, i.e. ‘bacteriostatic’. This classification is applied in major textbooks of medicine and infectious diseases, clinical guidelines and advertisements...
Data sources and searches
With the help of an experienced librarian with expertise in literature search for systematic reviews and meta-analyses, we performed an electronic search of OVID MEDLINE, EMBASE and The Cochrane Central Register of Controlled Trials (CENTRAL). We also searched relevant references of included studies and conference proceedings using the Web of Science and Scopus databases. No time limits were applied. The search strategy is displayed in detail in Supplementary Data.
Study selection
We included all randomized controlled trials comparing bacteriostatic versus bactericidal antibiotics in patients with serious bacterial infections requiring hospitalization. There was no restriction by study site/country or follow-up period and there was no restriction by dose, frequency or method of drug administration. One author (J. N.) screened the title and abstract of each reference identified by the search and applied the inclusion criteria. For possibly relevant articles, the full-te...
Data extraction and quality assessment
Two out of the three authors (J. N., G. O. and S. P. K.) independently extracted data from included trials. Data extraction was performed using a standardized data collection form. When missing data were encountered, the corresponding authors were contacted to retrieve them. For the assessment of clinical cure, data from ITT populations were extracted if possible. Some studies did not report the clinical cure rates of the ITT population or—in case of older studies—did not discern between diff...
Relapse
In 12 studies, relapse rates were reported.7,8,17,18,20,34,35,37,39–42 Five studies included relapse rates in the clinical cure rate endpoint.17,18,35,39,42 In the remaining seven studies, differences in relapse rates between bacteriostatic and bactericidal antibiotics were not significant (RR, 0.76; 95% CI, 0.43–1.35; P= 0.51; data not shown).
Study quality
The quality of included studies was variable (Supplementary Data). More than half of studies (17/33) were unblinded, resulting in significant risk of performance bias. More than 50% of studies were sponsored by the pharmaceutical company that manufactured the respective drug and were thus regarded to be at high risk of reporting bias. Funnel plots did not suggest publication bias (Supplementary Data).
In our meta-analysis comparing bactericidal with bacteriostatic antibiotics, no significant differences in clinical cure rates were found in the diseases under study. Subgroup analysis even suggested that linezolid may have better clinical cure rates if compared with its bactericidal comparators. This subgroup included severely ill patients with co...
We are thankful for fruitful discussions with Rainer Weber, Nicolas Müller, Jan S. Fehr, Dominique L. Braun, Huldrych F. Guenthard, Ulrich Matt, Elisabeth and Titus Nemeth.
- Johannes Nemeth, Gabriela Oesch, Stefan P. Kuster
- 2015
May 4, 2022 · Overview of Antibacterial Drugs. By Brian J. Werth, PharmD, University of Washington School of Pharmacy. Reviewed/Revised May 2022. View Patient Education. Selection and Use of Antibiotics |. Antibiotic Resistance. Antibacterial drugs are derived from bacteria or molds or are synthesized de novo.
Oct 24, 2013 · Antibiotics cure infections by influencing bacterial growth or viability. Antibiotics can be divided to two groups on the basis of their effect on microbial cells through two main mechanisms, which are either bactericidal or bacteriostatic. Bactericidal antibiotics kill the bacteria and bacteriostatic antibiotics suppress the growth of bacteria ...
- Silvie Bernatová, Ota Samek, Zdeněk Pilát, Mojmír Serý, Jan Ježek, Petr Jákl, Martin Siler, Vladisla...
- 10.3390/molecules181113188
- 2013
- Molecules. 2013 Nov; 18(11): 13188-13199.
Erythromycin is active against most gram-positive bacteria; some gram-negative bacteria, including Neisseria, Bordetella, Brucella, Campylobacter, and Legionella; and Treponema, Chlamydia, and Mycoplasma. The emergence of resistance to erythromycin is closely associated with its use and is often plasmid mediated.
